Portfolio Holdings Detail for ISIN IE00BF4RFH31

Stock Name / Fund	iShares MSCI World Small Cap UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares III Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300PZLRJB7M8H1057
ETF Ticker	WSML(USD) LSE
ETF Ticker	WLDS(GBP) LSE
ETF Ticker	IUSN(EUR) F
ETF Ticker	IUSN.DE(EUR) CXE
ETF Ticker	WLDS.LS(GBP) CXE
ETF Ticker	WSML.LS(USD) CXE
ETF Ticker	WSML.L(GBP) LSE
ETF Ticker	WLDS.L(GBP) LSE

Holdings detail for SYRE

Show aggregate SYRE holdings

News associated with SYRE

Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) from a sell rating to a hold rating in a research report sent to investors on Monday. Separately, Wedbush reiterated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Wednesday, August 6th. Two […] - 2025-09-09 02:57:04

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $53.40

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price […] - 2025-09-08 02:32:51

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $53.40 Average PT from Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given an average recommendation of “Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year […] - 2025-08-14 02:31:05

XTX Topco Ltd Acquires Shares of 28,499 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

XTX Topco Ltd acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the first quarter, Holdings Channel reports. The institutional investor acquired 28,499 shares of the company’s stock, valued at approximately $460,000. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the […] - 2025-08-08 04:38:55

The Math Shows SCHA Can Go To $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:38

Victory Capital Management Inc. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Victory Capital Management Inc. decreased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 251,846 shares of the company’s stock after selling 16,230 shares during the quarter. Victory Capital Management Inc.’s […] - 2025-07-28 05:02:49

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price […] - 2025-07-17 05:10:58

122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 122,153 shares of the company’s stock, valued at approximately $2,844,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.24% […] - 2025-06-03 05:35:02

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 22,741 shares of the company’s stock after acquiring an additional 916 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Spyre Therapeutics […] - 2025-05-30 04:48:57

Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average […] - 2025-05-06 02:32:52

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Barclays PLC

Barclays PLC lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 16.7% in the fourth quarter, Holdings Channel reports. The firm owned 123,071 shares of the company’s stock after acquiring an additional 17,604 shares during the period. Barclays PLC’s holdings in Spyre Therapeutics were worth $2,866,000 as of its most recent filing […] - 2025-04-30 05:15:05

Legal & General Group Plc Has $873,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Legal & General Group Plc grew its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,490 shares of the company’s stock after purchasing an additional 4,824 shares during the quarter. […] - 2025-04-28 04:56:53

Vanguard Group Inc. Purchases 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Vanguard Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 13.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,846,473 shares of the company’s stock after acquiring an additional 330,553 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Spyre Therapeutics worth $66,266,000 as of […] - 2025-04-11 05:40:57

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Average Price Target from Brokerages

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received an average rating of “Buy” from the ten analysts that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price […] - 2025-04-11 02:54:51

Corebridge Financial Inc. Sells 1,299 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Corebridge Financial Inc. lowered its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 7.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 17,213 shares of the company’s stock after selling 1,299 shares during the period. Corebridge Financial Inc.’s holdings in Spyre Therapeutics […] - 2025-04-10 04:49:04

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,604,508 shares of the company’s stock after acquiring an additional 97,308 shares during the quarter. Wellington Management Group LLP’s holdings in Spyre Therapeutics were worth $37,353,000 […] - 2025-04-07 06:35:09

Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Schroder Investment Management Group bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 113,620 shares of the company’s stock, valued at approximately $2,561,000. Schroder Investment Management Group owned about 0.22% of Spyre […] - 2025-04-07 05:10:58

Natixis Advisors LLC Invests $403,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Natixis Advisors LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) during the fourth quarter, Holdings Channel reports. The firm bought 17,300 shares of the company’s stock, valued at approximately $403,000. Several other large investors have also added to or reduced their stakes in SYRE. Barclays PLC increased its holdings in […] - 2025-03-28 06:04:54

Wolfe Research Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE)

Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $27.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 46.74% from the company’s previous close. Several other equities […] - 2025-03-20 04:22:57

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of “Buy” from Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-03-14 04:25:02

iShares MSCI World Small Cap UCITS ETF USD (Acc) SYRE holdings

Date	Number of SYRE Shares Held	Base Market Value of SYRE Shares	Local Market Value of SYRE Shares	Change in SYRE Shares Held	Change in SYRE Base Value	Current Price per SYRE Share Held	Previous Price per SYRE Share Held
2025-10-15 (Wednesday)	33,502	USD 743,409	USD 743,409
2025-10-10 (Friday)	33,289	USD 637,151	USD 637,151
2025-10-08 (Wednesday)	33,289	USD 588,550	USD 588,550
2025-10-07 (Tuesday)	33,289	USD 533,290	USD 533,290	146	USD -19,204	USD 16.02	USD 16.67
2025-10-06 (Monday)	33,143	USD 552,494	USD 552,494	0	USD 25,852	USD 16.67	USD 15.89
2025-10-03 (Friday)	33,143	USD 526,642	USD 526,642	0	USD -2,983	USD 15.89	USD 15.98
2025-10-02 (Thursday)	33,143	USD 529,625	USD 529,625	0	USD -15,909	USD 15.98	USD 16.46
2025-10-01 (Wednesday)	33,143	USD 545,534	USD 545,534	0	USD -9,943	USD 16.46	USD 16.76

Share Trades of SYRE by Blackrock for IE00BF4RFH31

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-07	BUY	146			16.020*		21.16
2025-09-08	SELL	-288			16.630*		21.40 Profit of 6,165 on sale
2025-08-15	BUY	142			16.950*		21.43
2025-07-29	BUY	142			16.770*		21.53
2025-07-14	BUY	288			16.410*		21.73
2025-06-30	BUY	288			14.970*		21.98
2025-06-25	BUY	432			15.720*		22.10
2025-06-20	SELL	-73			15.010*		22.24 Profit of 1,623 on sale
2025-06-12	SELL	-576			17.710*		22.48 Profit of 12,946 on sale
2025-06-02	BUY	222			15.400*		22.78
2025-05-28	BUY	146			15.080*		22.94
2025-05-14	BUY	73			14.800*		23.56
2025-05-13	BUY	146			14.750*		23.63
2025-05-07	BUY	219			12.710*		23.95
2025-04-28	BUY	72			14.670*		24.51
2025-04-16	BUY	962			12.420*		25.30
2025-04-14	BUY	148			13.020*		25.53
2025-04-08	SELL	-148			11.800*		26.04 Profit of 3,854 on sale
2025-04-04	SELL	-148			12.790*		26.31 Profit of 3,893 on sale
2025-03-28	BUY	720			17.940*		26.72
2025-03-12	SELL	-144			18.880*		27.91 Profit of 4,019 on sale
2025-03-04	SELL	-144			18.220*		28.47 Profit of 4,099 on sale
2025-02-26	SELL	-284			19.000*		28.97 Profit of 8,228 on sale
2025-02-13	BUY	73			22.680*		29.89
2025-02-12	BUY	288			23.270*		29.99
2025-01-27	BUY	71			20.820*		31.59
2025-01-23	BUY	71			21.810*		31.97
2024-12-09	BUY	1,656			26.810*		32.60
2024-12-04	BUY	90			27.990*		32.97
2024-12-03	BUY	132			27.270*		33.10
2024-11-19	BUY	264			26.900*		35.08
2024-11-18	BUY	88			28.670*		35.28
2024-11-12	BUY	172			35.820*		35.26
2024-11-11	BUY	43			39.350*		34.98
2024-11-11	BUY	43			39.350*		34.98
2024-11-07	BUY	210			37.690*		34.39
2024-11-07	BUY	210			37.690*		34.39
2024-10-23	BUY	86			33.610*		33.58
2024-10-23	BUY	86			33.610*		33.58

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SYRE

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer